Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials
Background: The upregulated expression of BET proteins is closely associated with the occurrence and development of hematological malignancies and solid tumors. Several BET inhibitors have been developed, and some have been in phase I/II of clinical trials. Here, the safety, efficacy, and pharmacody...
Saved in:
Main Authors: | Yanli Sun (Author), Jie Han (Author), Zhanzhao Wang (Author), Xuening Li (Author), Yanhua Sun (Author), Zhenbo Hu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bromodomain and Extra-Terminal Protein Inhibitors: Biologic Insights and Therapeutic Potential in Pediatric Brain Tumors
by: Andrew Groves, et al.
Published: (2022) -
Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases
by: Dayu Wu, et al.
Published: (2022) -
Efficacy and safety of FLT3 inhibitors in monotherapy of hematological and solid malignancies: a systemic analysis of clinical trials
by: Yuying Zhao, et al.
Published: (2024) -
Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment
by: Xu-Sheng Huang, et al.
Published: (2022) -
Liver dysfunction in children with hematologic malignancy or solid tumor
by: Rita Carmelia, et al.
Published: (2016)